The case of Gilead's Viread program for poor countries is becoming a case-study in how the best of intentions by a drug company can become entangled in a series of bureaucratic snafus. The AIDS drug is being provided at cost, but dealing with a myriad of governments and the WHO has limited the flow of medicines to a trickle. Report (WSJ sub. req.)